Stratec (SBS) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
14 Aug, 2026Executive summary
Q2 2026 performance improved significantly, narrowing the year-on-year gap in sales and earnings by the end of H1 2026, with strong momentum in the system business and robust free cash flow.
Profitability nearly matched the prior year, supported by cost discipline and strong demand for lifecycle management projects.
FY 2026 guidance confirmed, with growth expected from strong year-end business volumes and backend-loaded sales.
High customer demand for lifecycle management projects and successful transfer of new developments to series production.
Financial highlights
H1 2026 revenues were €112.5 million, down 5.1% nominally and 3.3% at constant currency year-over-year.
Adjusted EBIT was €7.7 million (margin 6.9%), slightly below the prior year; Q2 adjusted EBIT up 125.3% year-over-year.
Free cash flow improved to €23.5 million from negative €14.7 million last year; operating cash flow rose to €29.7 million from negative €5.8 million.
Adjusted net income was €4.1 million (EPS €0.34); reported IFRS net income was €2.4 million (EPS €0.20).
Equity ratio increased to 58.1% as of June 30, 2026.
Outlook and guidance
Full-year 2026 sales guidance confirmed: medium to high single-digit percentage growth at constant currency.
Adjusted EBIT margin for 2026 expected around 10%, with investment ratio targeted at 6.5–8.5% of sales.
Growth is expected to be heavily backend-loaded, with Q4 contributing up to 35% of annual sales.
2025–2028 CAGR expected at 6–8%, accelerating to 10–12% for 2028–2030; adjusted EBIT margin targets: at least 13% by 2028, 15% by 2030.
Workforce expected to remain stable or expand slightly.
Latest events from Stratec
- Q1 2026 sales and margins fell, but cash flow improved; growth targets and ESG goals remain strong.SBS
Corporate presentation - Sales declined in Q1 2026, but strong cash flow and a robust growth pipeline support future targets.SBS
Investor presentation - Sales and margins fell, but free cash flow surged and 2026 guidance was reaffirmed.SBS
Q1 2026 - Stable 2025 sales and margins, strong Q4 systems growth, and positive long-term outlook.SBS
Q4 2025 - Recurring revenue dominates as growth resumes in 2025, driven by innovation and M&A focus.SBS
Health Care Conference - Sales down 6.1% Y/Y; margins stable; Q4 rebound expected from new orders and deliveries.SBS
Q3 2024 - Margins and cash flow improved despite lower sales; 2024 guidance remains unchanged.SBS
Q2 2024 - Margin and cash flow gains in 2024; 2025 to see modest growth and margin normalization.SBS
Q4 2024 - Stable margins and recurring revenues support growth as innovation and M&A drive recovery.SBS
43rd Annual J.P. Morgan Healthcare Conference 2025